Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy
NCT02412462
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
15
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Tumor
Metastatic Cancer
Interventions
DRUG:
AB-16B5
Sponsor
Alethia Biotherapeutics